Lucentis Market, By Indication (Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), and Diabetic Macular Edema (DME)), By Dosage Strength (0.5 mg 10 mg/mL solution and 0.3 mg 6 mg/mL solution), B

The Global Lucentis Market is estimated to be valued at USD 739.1 Mn in 2025 and is expected to reach USD 64.1 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of -29.5% from 2025 to 2032. The global Lucentis market has witnessed significant growth in recent years, driven by the increasing prevalence of eye disorders such as age-related macular degeneration (AMD) and diabetic retinopathy. Lucentis, a monoclonal antibody developed by Genentech and Novartis, has revolutionized the treatment of these conditions by targeting the vascular endothelial growth factor (VEGF) protein, which plays a crucial role in the development of abnormal blood vessels in the eye. As the global population continues to age and the incidence of diabetes rises, the demand for effective treatments like Lucentis is expected to surge. This introduction provides an overview of the Lucentis market, its key drivers, and the potential for growth in the coming years.

Market Dynamics

The global Lucentis market is driven by several factors, including the increasing prevalence of eye disorders such as AMD and diabetic retinopathy, the growing elderly population, and the rising awareness of effective treatments. AMD is the leading cause of vision loss among older adults, and with the global population aging rapidly, the number of individuals affected by this condition is expected to rise significantly in the coming years. Similarly, the growing incidence of diabetes worldwide is contributing to the increased prevalence of diabetic retinopathy, further fueling the demand for Lucentis. However, the market growth may be restrained by factors such as the high cost of treatment, the availability of alternative therapies, and the potential side effects associated with Lucentis injections. Despite these challenges, the market presents significant opportunities for growth, driven by the development of new formulations, the expansion of indications, and the increasing adoption of Lucentis in emerging markets.

Key Features of the Study

• This report provides in-depth analysis of the global Lucentis market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global Lucentis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Genentech, Inc. and Novartis AG.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global Lucentis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Lucentis market.

Market Segmentation

• Indication Insights (Revenue, USD Mn, 2020 - 2032)
• Neovascular (Wet) Age-Related Macular Degeneration (AMD)
• Macular Edema Following Retinal Vein Occlusion (RVO)
• Diabetic Macular Edema (DME)
• Dosage Strength Insights (Revenue, USD Mn, 2020 - 2032)
• 5 mg 10 mg/mL solution
• 3 mg 6 mg/mL solution
• Packaging Insights (Revenue, USD Mn, 2020 - 2032)
• Pre-filled syringe
• Single-use glass vial
• Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Genentech, Inc. (Part of Roche)
• Novartis AG

Show more